Peer-reviewed publication in Clinical & Experimental Allergy reveals potential disease-modifying effect of Mabylon’s allergen-neutralizing antibodies: Zurich, Switzerland Thursd ...
LogiPharma launches Air Cargo Hub for 2027, to connect directly with pharma and life sciences supply chain leaders: Derbyshire, UK Thursday, November 5, 2026, 17:00 Hrs [IST] Logi ...
Dr. Reddy’s receives marketing authorization for generic semaglutide injection in Brazil: Our Bureau, Mumbai Thursday, November 5, 2026, 16:15 Hrs [IST] Dr Reddy’s Laboratorie ...
Signant Health introduces Signant SignalSpace, a connected environment for clinical trial data and workflows: Philadelphia Thursday, November 5, 2026, 16:00 Hrs [IST] Signant Heal ...
IGI to present updated clinical data for ISB 2001 in relapsed/refractory multiple myeloma at 68th ASH AGM: Our Bureau, Mumbai Thursday, November 5, 2026, 15:30 Hrs [IST] Ichnos Gl ...
Aurobindo Pharma Limited announced its consolidated financial results for the quarter ended September 30, 2026. The company's revenue from operations stood at Rs. 10,263 crore, reporting an increase ...
Tens of thousands of patients to take part in new NHS blood test trial to help spot cancers earlier: United Kingdom Thursday, November 5, 2026, 15:00 Hrs [IST] A world-leading new ...
Thakral leases land to Manipal Hospitals, to develop and operate a multi-speciality hospital at Gurugram, Delhi NCR: Our Bureau, Bengaluru Thursday, November 5, 2026, 14:40 Hrs [I ...
Apollo Hospitals in Q2 clocks 23% rise in revenue at Rs. 7,615 crore, PAT increases to 32% at Rs. 630 crore: Our Bureau, Bengaluru Thursday, November 5, 2026, 14:30 Hrs [IST] Apol ...
Ennature Bio Pharma lists on NSE and BSE on 4th November, 2026: Our Bureau, Bengaluru Thursday, November 5, 2026, 14:15 Hrs [IST] Ennature Bio Pharma listed on the National Stock ...
Genprex reports new research identifying TROP2 as a potential predictive biomarker to Reqorsa gene therapy in lung cancer: Austin, Texas Thursday, November 5, 2026, 14:00 Hrs [IST ...
The sirolimus-coated balloon (SCB) strategy has demonstrated non-inferiority to contemporary everolimus-eluting stents (EES) in treating de novo coronary artery disease, according to results from the ...